Search

 
 
 
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

After a High-Speed Decade, Agios CEO David Schenkein to Step Aside

AFTER A HIGH-SPEED DECADE, AGIOS CEO DAVID SCHENKEIN TO STEP ASIDE

David Schenkein, the longtime CEO of Agios Pharmaceuticals, will step aside next year after transforming what was once a high-risk...

 
 
 
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

BIO ROUNDUP: DRUG PRICES, CRISPR CAVEATS, RUBIUS IPO POP & MORE

After nearly two years of all smoke, no fire around President Trump's promise to curtail drug prices, there's finally some glimmer...

 
 
 
 
 
 

PROCESS AUTOMATION ENGINEER I/II - GENENTECH - OCEANSIDE, CA

Bachelor's or Master's degree in Engineering (Chemical, Mechanical, Electrical, or Computer Science preferred) and 5 years experience,...

 
 
 

MEDIA PREP TECH

Company: Genentech Job Title: Media Prep Tech Location: South San Francisco, CA Contract Length: 6+ months **Note: Will NOT drive a...

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

 
 
 
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

BIO ROUNDUP: CMS BACKS CANCER TESTS, RIGHT TO TRY PASSES, ABBVIE SINKS

We'll start this week's roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA...

GENENTECH'S TECENTRIQ IMPRESSES AGAIN IN LATE-STAGE KIDNEY CANCER TRIAL

The study met its co-primary endpoint of investigator-assessed progression-free survival in people whose disease expressed the PD-L1...

 
 
 
Every New FDA Drug Approval in 2017

EVERY NEW FDA DRUG APPROVAL IN 2017

2017 was a busy year for the FDA. With 46 approvals, the year far outpaced the 22 approvals in 2016. We've already shown you every...

GENENTECH, DICE ALLY TO GO AFTER HARD-TO-DRUG TARGETS

Genentech has entered into a multi-target drug discovery deal with DiCE Molecules. The Roche unit is handing over an upfront fee and...

 
 
 
 
 
 
Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More

BIO ROUNDUP: MIGRAINE DATA, CANCER DRUG COMBOS, AZAR HEARING & MORE

A pair of migraine drugs made a splash in biotech news this week with published data suggesting that they can reduce the frequency...